ArticlesComparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
Introduction
Major consequences in rheumatoid arthritis are related to the disease itself and its associated comorbidities. Although outcomes have improved over the past few decades with the advent of new treatments and therapeutic approaches, patients still have substantial functional disability and loss of ability to work.1, 2 Intensive but safe treatments have the potential to improve long-term outcomes.
Remission is the best outcome for early therapy. There are several definitions of remission based on clinical criteria, but disease activity score in 28 joints (DAS28) is the most commonly used validated method for the measurement of remission,3, 4, 5 which has been recognised in the European League Against Rheumatism working group recommendations for the management of early rheumatoid arthritis as a goal of therapy.6 Remission is best achieved by reducing or eliminating inflammation, thereby stopping radiographic progression at an early stage when the disease is most destructive and before joint damage occurs.7 Thus, remission has become the aim of management of early rheumatoid arthritis, and this aim needs to be included in trial design.8
Disease-modifying antirheumatic drugs (DMARDs), alone or in combination, have been the mainstay of treatment for rheumatoid arthritis.9, 10, 11 Before the recent era of biological therapy, clinical remission was not commonly reported.12 New treatment strategies advocate the use of earlier, more intensive therapy than previously applied to prevent joint damage and functional disability.13 In this context, remission has emerged as a realistic goal, especially in patients with early rheumatoid arthritis.6, 14 Support for remission in disease activity and radiographic outcomes as a primary endpoint in clinical trials has grown as treatment options have improved and combined-treatment regimens have emerged.15, 16, 17, 18, 19, 20 Recent data indicate that conventional disease modifying antirheumatic drugs might not halt radiographic progression, even when they produce clinical remission, which could be attributed to incomplete suppression of synovitis.16, 18, 21 Combination therapy with methotrexate and an anti-tumour-necrosis-factor (TNF) agent seems to be best in this respect, nearly halting structural progression and producing clinically relevant responses.15, 22
The combination of methotrexate and etanercept in early rheumatoid arthritis (COMET) trial investigates clinical remission, radiographic non-progression, and restoration of function in a continuing 2-year study comparing the effects of combined etanercept (a fully human TNF soluble receptor) and methotrexate with those of methotrexate alone in patients with moderate-to-severe, active, early rheumatoid arthritis. The aim of this study was to investigate aggressive therapy for early disease with combined treatment as the regimen of choice to achieve clinical and radiographic treatment targets and normalisation of function. The results in this report are for the first year (period 1).
Section snippets
Patients
Participants were enrolled at 70 sites in Europe, Latin America, Asia, and Australia from October, 2004, to February, 2006. Patients were age 18 years or older with diagnosis of adult-onset rheumatoid arthritis, disease duration of at least 3 months but not more than 2 years, DAS28 of 3·2 or more, and either Westergren ESR of 28 mm/h or more or C-reactive protein of 20 mg/L or more. Patients were ineligible if they had received previous treatment with methotrexate, etanercept, or another TNF
Results
542 patients from 22 countries participated in this trial; 472 (87%) were from Europe and Australia, and the remainder were from Latin America and Asia. 528 patients (263 on methotrexate alone and 265 on combined treatment) were available for clinical efficacy analysis; all 542 were included in the safety analysis. 230 in the methotrexate group and 246 in the combined-treatment group had data that were valid for radiographic analysis. At baseline, 487 (92%) of 528 patients had DAS28 >5·1,
Discussion
Half the patients on combination therapy with etanercept and methotrexate successfully achieved clinical remission (as judged with DAS28), significantly more than those receiving conventional methotrexate monotherapy. The primary outcome had a higher threshold of clinical response than in previous large randomised, double blind, controlled clinical trials for rheumatoid arthritis.9, 11, 16, 30 Almost two-thirds of patients in the combination group achieved low disease activity (DAS28 ≤3·2),
References (39)
- et al.
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
Lancet
(1997) Early rheumatoid arthritis: strategies for prevention and management
Best Pract Res Clin Rheumatol
(2007)- et al.
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in subjects with rheumatoid arthritis
Lancet
(2004) - et al.
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial
Lancet
(1999) - et al.
Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
Lancet
(1989) - et al.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
Lancet
(2004) - et al.
Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs—results of the British Rheumatoid Outcome Study Group randomised controlled clinical trial
Rheumatology
(2006) - et al.
Functional disability in rheumatoid arthritis patients compared with a community population in Finland
Arthritis Rheum
(2003) - et al.
Modified disease activity scores that include twenty-eight-joint counts—development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
Arthritis Rheum
(1995) - et al.
Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score
Br J Rheumatol
(1996)
A comparison of validity of single variables and composed indices for measuring disease activity in rheumatoid arthritis
Ann Rheum Dis
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
Ann Rheum Dis
Radiographic progression in rheumatoid arthritis: does it reflect outcome? does it reflect treatment?
Ann Rheum Dis
Early rheumatoid arthritis: time to aim for remission?
Ann Rheum Dis
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
N Engl J Med
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
Ann Rheum Dis
Remission in rheumatoid arthritis
J Rheumatol
Remission as the treatment goal—the FIN-RACo trial
Clin Exp Rheumatol
The PREMIER study: a multicenter, randomised, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Arthritis Rheum
Cited by (709)
IFABP2 as a new prognostic biomarker for secondary non-response in rheumatoid arthritis
2023, International ImmunopharmacologyRenal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review
2023, Kidney International